메뉴 건너뛰기




Volumn , Issue , 2008, Pages 151-167

Clinical pharmacology of opioids: Basic pharmacology

Author keywords

[No Author keywords available]

Indexed keywords


EID: 70349282724     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter
Times cited : (1)

References (132)
  • 1
    • 30044449981 scopus 로고    scopus 로고
    • A multidimensional model for understanding cancer pain
    • Wool MS, Mor V. A multidimensional model for understanding cancer pain. Cancer Investigation. 2005; 23: 727-34
    • (2005) Cancer Investigation , vol.23 , pp. 727-734
    • Wool, M.S.1    Mor, V.2
  • 2
    • 0038615188 scopus 로고    scopus 로고
    • Pain, depression, and fatigue
    • NIH State-of-the-Science Statement on Symptom Management in Cancer. Pain, depression, and fatigue. NIH Consensus and State-of-the-Science Statements. 2002; 19: 1-29
    • (2002) NIH Consensus and State-Of-The-Science Statements , vol.19 , pp. 1-29
  • 4
    • 0003527864 scopus 로고    scopus 로고
    • 2nd edn. Geneva: World Health Organization
    • World Health Organization. Cancer pain relief, 2nd edn. Geneva: World Health Organization, 1996
    • (1996) Cancer Pain Relief
  • 5
    • 0035060745 scopus 로고    scopus 로고
    • Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness
    • Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. Journal of Pain and Symptom Management. 2001; 21: 338-54
    • (2001) Journal of Pain and Symptom Management , vol.21 , pp. 338-354
    • Mercadante, S.1    Portenoy, R.K.2
  • 6
    • 0019439185 scopus 로고
    • Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain
    • Hanks GW, Twycross RG, Lloyd JW. Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain. Anaesthesia. 1981; 36: 37-9
    • (1981) Anaesthesia , vol.36 , pp. 37-39
    • Hanks, G.W.1    Twycross, R.G.2    Lloyd, J.W.3
  • 7
    • 0034046878 scopus 로고    scopus 로고
    • Bedside perspectives on the use of opioids: Transferring results of clinical research into practice
    • Ravenscroft P, Schneider J. Bedside perspectives on the use of opioids: transferring results of clinical research into practice. Clinical and Experimental Pharmacology and Physiology. 2000; 27: 529-32
    • (2000) Clinical and Experimental Pharmacology and Physiology , vol.27 , pp. 529-532
    • Ravenscroft, P.1    Schneider, J.2
  • 9
  • 10
    • 0028882923 scopus 로고
    • The cloned mu, delta and kappa receptors and their endogenous ligands: Evidence for two opioid peptide recognition cores
    • Mansour A, Hoversten MT, Taylor LP et al. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Research. 1995; 700: 89-98
    • (1995) Brain Research , vol.700 , pp. 89-98
    • Mansour, A.1    Hoversten, M.T.2    Taylor, L.P.3
  • 11
    • 0028971215 scopus 로고
    • Orphanin FQ: A neuropeptide that activates an opioid-like G proteincoupled receptor
    • Reinscheid RK, Nothacker HP, Bourson A et al. Orphanin FQ: a neuropeptide that activates an opioid-like G proteincoupled receptor. Science. 1995; 270: 792-4
    • (1995) Science , vol.270 , pp. 792-794
    • Reinscheid, R.K.1    Nothacker, H.P.2    Bourson, A.3
  • 12
    • 0031553387 scopus 로고    scopus 로고
    • Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor
    • Meunier JC. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. European Journal of Pharmacology. 1997; 340: 1-15
    • (1997) European Journal of Pharmacology , vol.340 , pp. 1-15
    • Meunier, J.C.1
  • 13
    • 0026550559 scopus 로고
    • Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: Supraand sub-additivity
    • Horan P, Tallarida RJ, Haaseth RC et al. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supraand sub-additivity. Life Sciences. 1992; 50: 1535-41
    • (1992) Life Sciences , vol.50 , pp. 1535-1541
    • Horan, P.1    Tallarida, R.J.2    Haaseth, R.C.3
  • 14
    • 0031835859 scopus 로고    scopus 로고
    • Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord
    • He L, Lee NM. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. Journal of Pharmacology and Experimental Therapeutics. 1998; 285: 1181-6
    • (1998) Journal of Pharmacology and Experimental Therapeutics , vol.285 , pp. 1181-1186
    • He, L.1    Lee, N.M.2
  • 15
    • 0030045115 scopus 로고    scopus 로고
    • An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice
    • Kest B, Lee CE, McLemore GL, Inturrisi CE. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Research Bulletin. 1996; 39: 185-8
    • (1996) Brain Research Bulletin , vol.39 , pp. 185-188
    • Kest, B.1    Lee, C.E.2    McLemore, G.L.3    Inturrisi, C.E.4
  • 18
    • 0033529255 scopus 로고    scopus 로고
    • The mu opiate receptor as a candidate gene for pain: Polymorphisms, variations in expression, nociception, and opiate responses
    • Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96: 7752-5
    • (1999) Proceedings of the National Academy of Sciences of the United States of America , vol.96 , pp. 7752-7755
    • Uhl, G.R.1    Sora, I.2    Wang, Z.3
  • 19
    • 33646833956 scopus 로고    scopus 로고
    • A highly selective kappaopioid receptor agonist with low addictive potential and dependence liability
    • Park HS, Lee HY, Kim YH et al. A highly selective kappaopioid receptor agonist with low addictive potential and dependence liability. Bioorganic and Medicinal Chemistry Letters. 2006; 16: 3609-13
    • (2006) Bioorganic and Medicinal Chemistry Letters , vol.16 , pp. 3609-3613
    • Park, H.S.1    Lee, H.Y.2    Kim, Y.H.3
  • 20
    • 33645070773 scopus 로고    scopus 로고
    • Opioid ligands with mixed mu/delta opioid receptor interactions: An emerging approach to novel analgesics
    • Ananthan S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. The AAPS Journal. 2006; 8: E118-25
    • (2006) The AAPS Journal , vol.8 , pp. E118-E125
    • Ananthan, S.1
  • 21
    • 0019845261 scopus 로고
    • Both mu and delta opiate receptors exist on the same neuron
    • Egan TM, North RA. Both mu and delta opiate receptors exist on the same neuron. Science. 1981; 214: 923-4
    • (1981) Science , vol.214 , pp. 923-924
    • Egan, T.M.1    North, R.A.2
  • 22
    • 0034668742 scopus 로고    scopus 로고
    • Heterodimerization of mu and delta opioid receptors: A role in opiate synergy
    • Gomes I, Jordan BA, Gupta A et al. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. Journal of Neuroscience. 2000; 20: RC110
    • (2000) Journal of Neuroscience , vol.20
    • Gomes, I.1    Jordan, B.A.2    Gupta, A.3
  • 23
    • 3042736193 scopus 로고    scopus 로고
    • Mu opiate receptor subtypes
    • Cadet P. Mu opiate receptor subtypes. Medical Science Monitor. 2004; 10: MS28-32
    • (2004) Medical Science Monitor , vol.10 , pp. MS28-MS32
    • Cadet, P.1
  • 24
    • 0035993849 scopus 로고    scopus 로고
    • Non-peptide opioid receptor ligands recent advances. Part I: Agonists
    • Kaczor A, Matosiuk D. Non-peptide opioid receptor ligands recent advances. Part I: agonists. Current Medicinal Chemistry. 2002; 9: 1567-89
    • (2002) Current Medicinal Chemistry , vol.9 , pp. 1567-1589
    • Kaczor, A.1    Matosiuk, D.2
  • 25
    • 0035252727 scopus 로고    scopus 로고
    • Incomplete cross tolerance and multiple mu opioid peptide receptors
    • Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends in Pharmacological Sciences. 2001; 22: 67-70
    • (2001) Trends in Pharmacological Sciences , vol.22 , pp. 67-70
    • Pasternak, G.W.1
  • 27
    • 28444479463 scopus 로고    scopus 로고
    • Diversity and complexity of the mu opioid receptor gene: Alternative pre-mRNA splicing and promoters
    • Pan YX. Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biology. 2005; 24: 736-50
    • (2005) DNA Cell Biology , vol.24 , pp. 736-750
    • Pan, Y.X.1
  • 28
    • 18844451788 scopus 로고    scopus 로고
    • Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm
    • Pan L, Xu J, Yu R et al. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience. 2005; 133: 209-20
    • (2005) Neuroscience , vol.133 , pp. 209-220
    • Pan, L.1    Xu, J.2    Yu, R.3
  • 29
    • 0029113905 scopus 로고
    • Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6 betaglucuronide receptor
    • Rossi GC, Pan YX, Brown GP, Pasternak GW. Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 betaglucuronide receptor. FEBS Letters. 1995; 369: 192-6
    • (1995) FEBS Letters , vol.369 , pp. 192-196
    • Rossi, G.C.1    Pan, Y.X.2    Brown, G.P.3    Pasternak, G.W.4
  • 32
    • 27744431653 scopus 로고    scopus 로고
    • The endogenous opioid system and clinical pain management
    • Holden JE, Jeong Y, Forrest JM. The endogenous opioid system and clinical pain management. AACN Clinical Issues. 2005; 16: 291-301
    • (2005) AACN Clinical Issues , vol.16 , pp. 291-301
    • Holden, J.E.1    Jeong, Y.2    Forrest, J.M.3
  • 34
    • 3242747490 scopus 로고    scopus 로고
    • Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart
    • Pepe S, van den Brink OW, Lakatta EG, Xiao RP. Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. Cardiovascular Research. 2004; 63: 414-22
    • (2004) Cardiovascular Research , vol.63 , pp. 414-422
    • Pepe, S.1    Van Den Brink, O.W.2    Lakatta, E.G.3    Xiao, R.P.4
  • 35
    • 0025581874 scopus 로고
    • Endogenous opioids, the enteric nervous system and gut motility
    • Kromer W. Endogenous opioids, the enteric nervous system and gut motility. Digestive Diseases. 1990; 8: 361-73
    • (1990) Digestive Diseases , vol.8 , pp. 361-373
    • Kromer, W.1
  • 36
    • 29144445369 scopus 로고    scopus 로고
    • Multiple opioid receptors on immune cells modulate intracellular signaling. Brain
    • Sharp BM. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain, Behavior, and Immunity. 2006; 20: 9-14
    • (2006) Behavior, and Immunity , vol.20 , pp. 9-14
    • Sharp, B.M.1
  • 38
    • 0016139515 scopus 로고
    • Sites of morphine induced analgesia in the primate brain: Relation to pain pathways
    • Pert A, Yaksh T. Sites of morphine induced analgesia in the primate brain: relation to pain pathways. Brain Research. 1974; 80: 135-40
    • (1974) Brain Research , vol.80 , pp. 135-140
    • Pert, A.1    Yaksh, T.2
  • 40
    • 13844276195 scopus 로고    scopus 로고
    • Differentiation of opioid receptor preference by [Dmt1]endomorphin-2mediated antinociception in the mouse
    • Jinsmaa Y, Fujita Y, Shiotani K et al. Differentiation of opioid receptor preference by [Dmt1]endomorphin-2mediated antinociception in the mouse. European Journal of Pharmacology. 2005; 509: 37-42
    • (2005) European Journal of Pharmacology , vol.509 , pp. 37-42
    • Jinsmaa, Y.1    Fujita, Y.2    Shiotani, K.3
  • 41
    • 33746305665 scopus 로고    scopus 로고
    • Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt(1)]endomorphin-1. Pharmacology
    • Jinsmaa Y, Marczak E, Fujita Y et al. Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt(1)]endomorphin-1. Pharmacology, Biochemistry, and Behavior. 2006; 84: 252-8
    • (2006) Biochemistry, and Behavior , vol.84 , pp. 252-258
    • Jinsmaa, Y.1    Marczak, E.2    Fujita, Y.3
  • 42
    • 0034450970 scopus 로고    scopus 로고
    • Endomorphin-1 and endomorphin-2: Pharmacology of the selective endogenous mu-opioid receptor agonists
    • Horvath G. Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous mu-opioid receptor agonists. Pharmacology and Therapeutics. 2000; 88: 437-63
    • (2000) Pharmacology and Therapeutics , vol.88 , pp. 437-463
    • Horvath, G.1
  • 43
    • 0035993110 scopus 로고    scopus 로고
    • Isolation and distribution of endomorphins in the central nervous system
    • Zadina JE. Isolation and distribution of endomorphins in the central nervous system. Japanese Journal of Pharmacology. 2002; 89: 203-08
    • (2002) Japanese Journal of Pharmacology , vol.89 , pp. 203-208
    • Zadina, J.E.1
  • 44
    • 4644343161 scopus 로고    scopus 로고
    • Multiple opiate receptors: Deja vu all over again
    • Pasternak GW. Multiple opiate receptors: deja vu all over again. Neuropharmacology. 2004; 47 (Suppl. 1): 312-23
    • (2004) Neuropharmacology , vol.47 , pp. 312-323
    • Pasternak, G.W.1
  • 45
    • 0038014065 scopus 로고    scopus 로고
    • Utilizing functional genomics to identify new pain treatments: The example of nociceptin
    • Meunier JC. Utilizing functional genomics to identify new pain treatments: the example of nociceptin. American Journal of Pharmacogenomics. 2003; 3: 117-30
    • (2003) American Journal of Pharmacogenomics , vol.3 , pp. 117-130
    • Meunier, J.C.1
  • 46
    • 0026512239 scopus 로고
    • Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic
    • Raffa RB, Friderichs E, Reimann W et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. Journal of Pharmacology and Experimental Therapeutics. 1992; 260: 275-85
    • (1992) Journal of Pharmacology and Experimental Therapeutics , vol.260 , pp. 275-285
    • Raffa, R.B.1    Friderichs, E.2    Reimann, W.3
  • 47
    • 33646455888 scopus 로고    scopus 로고
    • Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects
    • Yuan CS, Israel RJ. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opinion on Investigational Drugs. 2006; 15: 541-52
    • (2006) Expert Opinion on Investigational Drugs , vol.15 , pp. 541-552
    • Yuan, C.S.1    Israel, R.J.2
  • 48
    • 0035138992 scopus 로고    scopus 로고
    • ADL 82698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia
    • Liu SS, Hodgson PS, Carpenter RL, Fricke Jr. JR. ADL 82698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clinical Pharmacology and Therapeutics. 2001; 69: 66-71
    • (2001) Clinical Pharmacology and Therapeutics , vol.69 , pp. 66-71
    • Liu, S.S.1    Hodgson, P.S.2    Carpenter, R.L.3    Fricke, J.R.4
  • 49
    • 0034693398 scopus 로고    scopus 로고
    • Improved bioavailability to the brain of glycosylated Met-enkephalin analogs
    • Egleton RD, Mitchell SA, Huber JD et al. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Research. 2000; 881: 37-46
    • (2000) Brain Research , vol.881 , pp. 37-46
    • Egleton, R.D.1    Mitchell, S.A.2    Huber, J.D.3
  • 51
    • 0034729726 scopus 로고    scopus 로고
    • Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability
    • Bilsky EJ, Egleton RD, Mitchell SA et al. Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. Journal of Medicinal Chemistry. 2000; 43: 2586-90
    • (2000) Journal of Medicinal Chemistry , vol.43 , pp. 2586-2590
    • Bilsky, E.J.1    Egleton, R.D.2    Mitchell, S.A.3
  • 52
    • 0019493405 scopus 로고
    • Increased food and water intake produced in rats by opiate receptor agonists
    • Sanger DJ, McCarthy PS. Increased food and water intake produced in rats by opiate receptor agonists. Psychopharmacology. 1981; 74: 217-20
    • (1981) Psychopharmacology , vol.74 , pp. 217-220
    • Sanger, D.J.1    McCarthy, P.S.2
  • 53
    • 0031885078 scopus 로고    scopus 로고
    • Pathophysiology and treatment of opioidrelated myoclonus in cancer patients
    • Mercadante S. Pathophysiology and treatment of opioidrelated myoclonus in cancer patients. Pain. 1998; 74: 5-9
    • (1998) Pain , vol.74 , pp. 5-9
    • Mercadante, S.1
  • 55
    • 0024218061 scopus 로고
    • Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion
    • Kromer W. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacological Reviews. 1988; 40: 121-62
    • (1988) Pharmacological Reviews , vol.40 , pp. 121-162
    • Kromer, W.1
  • 57
    • 3242741057 scopus 로고    scopus 로고
    • Chronic fentanyl or buprenorphine infusion in the mouse: Similar analgesic profile but different effects on immune responses
    • Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain. 2004; 110: 385-92
    • (2004) Pain , vol.110 , pp. 385-392
    • Martucci, C.1    Panerai, A.E.2    Sacerdote, P.3
  • 58
    • 33745053647 scopus 로고    scopus 로고
    • Opioids and the immune system
    • Sacerdote P. Opioids and the immune system. Palliative Medicine. 2006; 20 (Suppl. 1): s9-15
    • (2006) Palliative Medicine , vol.20 , pp. s9-s15
    • Sacerdote, P.1
  • 59
    • 0034076414 scopus 로고    scopus 로고
    • The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients
    • Sacerdote P, Bianchi M, Gaspani L et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesthesia and Analgesia. 2000; 90: 1411-14
    • (2000) Anesthesia and Analgesia , vol.90 , pp. 1411-1414
    • Sacerdote, P.1    Bianchi, M.2    Gaspani, L.3
  • 63
    • 0003632704 scopus 로고    scopus 로고
    • Glenview, IL: American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine
    • American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain. Glenview, IL: American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine, 2001
    • (2001) Definitions Related to the Use of Opioids for the Treatment of Pain
  • 64
    • 84900450171 scopus 로고    scopus 로고
    • Clinical pharmacology-including tolerance
    • Sykes N, Fallon MT, Patt RB, London: Arnold Publishers
    • Schug SA, Cardwell HMD. Clinical pharmacology-including tolerance. In: Sykes N, Fallon MT, Patt RB (eds). Clinical pain management: cancer pain. London: Arnold Publishers, 2003: 33-62
    • (2003) Clinical Pain Management: Cancer Pain , pp. 33-62
    • Schug, S.A.1    Cardwell, H.M.D.2
  • 65
    • 0024325328 scopus 로고
    • Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model
    • Ling GS, Paul D, Simantov R, Pasternak GW. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sciences. 1989; 45: 1627-36
    • (1989) Life Sciences , vol.45 , pp. 1627-1636
    • Ling, G.S.1    Paul, D.2    Simantov, R.3    Pasternak, G.W.4
  • 66
    • 0023510867 scopus 로고
    • Cellular mechanisms of opioid tolerance: Studies in single brain neurons
    • Christie MJ, Williams JT, North RA. Cellular mechanisms of opioid tolerance: studies in single brain neurons. Molecular Pharmacology. 1987; 32: 633-8
    • (1987) Molecular Pharmacology , vol.32 , pp. 633-638
    • Christie, M.J.1    Williams, J.T.2    North, R.A.3
  • 67
    • 30644458052 scopus 로고    scopus 로고
    • Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine
    • Bagley EE, Chieng BC, Christie MJ, Connor M. Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine. British Journal of Pharmacology. 2005; 146: 68-76
    • (2005) British Journal of Pharmacology , vol.146 , pp. 68-76
    • Bagley, E.E.1    Chieng, B.C.2    Christie, M.J.3    Connor, M.4
  • 69
    • 0026518601 scopus 로고
    • Pain, opioid use, and survival in hospitalized patients with advanced cancer
    • Brescia FJ, Portenoy RK, Ryan M et al. Pain, opioid use, and survival in hospitalized patients with advanced cancer. Journal of Clinical Oncology. 1992; 10: 149-55
    • (1992) Journal of Clinical Oncology , vol.10 , pp. 149-155
    • Brescia, F.J.1    Portenoy, R.K.2    Ryan, M.3
  • 70
    • 12344271040 scopus 로고    scopus 로고
    • Opioids: Cellular mechanisms of tolerance and physical dependence
    • Bailey CP, Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Current Opinion in Pharmacology. 2005; 5: 60-8
    • (2005) Current Opinion in Pharmacology , vol.5 , pp. 60-68
    • Bailey, C.P.1    Connor, M.2
  • 72
    • 34247622406 scopus 로고    scopus 로고
    • Addiction to opioids in chronic pain patients: A literature review
    • Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: A literature review. European Journal of Pain. 2007; 11: 490-518
    • (2007) European Journal of Pain , vol.11 , pp. 490-518
    • Hojsted, J.1    Sjogren, P.2
  • 73
    • 0029622428 scopus 로고
    • The pharmacogenetics of codeine hypoalgesia
    • Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995; 5: 335-46
    • (1995) Pharmacogenetics , vol.5 , pp. 335-346
    • Sindrup, S.H.1    Brosen, K.2
  • 74
    • 0022497847 scopus 로고
    • Bioavailability of enteral tramadol formulations. 1st communication: Capsules
    • Lintz W, Barth H, Osterloh G, Schmidt-Bothelt E. Bioavailability of enteral tramadol formulations. 1st communication: capsules. Arzneimittel Forschung. 1986; 36: 1278-83
    • (1986) Arzneimittel Forschung , vol.36 , pp. 1278-1283
    • Lintz, W.1    Barth, H.2    Osterloh, G.3    Schmidt-Bothelt, E.4
  • 76
    • 0033901486 scopus 로고    scopus 로고
    • Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor
    • Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. NaunynSchmiedeberg’s Archives of Pharmacology. 2000; 362: 116-21
    • (2000) NaunynSchmiedeberg’s Archives of Pharmacology , vol.362 , pp. 116-121
    • Gillen, C.1    Haurand, M.2    Kobelt, D.J.3    Wnendt, S.4
  • 77
    • 13244260911 scopus 로고    scopus 로고
    • The role of tramadol in cancer pain treatment a review
    • Leppert W, Luczak J. The role of tramadol in cancer pain treatment a review. Supportive Care in Cancer. 2005; 13: 5-17
    • (2005) Supportive Care in Cancer , vol.13 , pp. 5-17
    • Leppert, W.1    Luczak, J.2
  • 78
    • 33746171436 scopus 로고    scopus 로고
    • Extended-release tramadol in the treatment of osteoarthritis: A multicenter, randomized, double-blind, placebo-controlled clinical trial
    • Gana TJ, Pascual ML, Fleming RR et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Current Medical Research and Opinion. 2006; 22: 1391-401
    • (2006) Current Medical Research and Opinion , vol.22 , pp. 1391-1401
    • Gana, T.J.1    Pascual, M.L.2    Fleming, R.R.3
  • 80
    • 33646530497 scopus 로고    scopus 로고
    • Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol
    • Epstein DH, Preston KL, Jasinski DR. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biological Psychology. 2006; 73: 90-9
    • (2006) Biological Psychology , vol.73 , pp. 90-99
    • Epstein, D.H.1    Preston, K.L.2    Jasinski, D.R.3
  • 81
    • 0032877110 scopus 로고    scopus 로고
    • Tramadol relieves pain and allodynia in polyneuropathy: A randomised, double-blind, controlled trial
    • Sindrup SH, Andersen G, Madsen C et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain. 1999; 83: 85-90
    • (1999) Pain , vol.83 , pp. 85-90
    • Sindrup, S.H.1    Ersen, G.2    Madsen, C.3
  • 83
    • 0042347905 scopus 로고    scopus 로고
    • In search of a role for the morphine metabolite morphine-3-glucuronide
    • Vaughan CW, Connor M. In search of a role for the morphine metabolite morphine-3-glucuronide. Anesthesia and Analgesia. 2003; 97: 311-12
    • (2003) Anesthesia and Analgesia , vol.97 , pp. 311-312
    • Vaughan, C.W.1    Connor, M.2
  • 84
    • 34250688393 scopus 로고    scopus 로고
    • The adverse effects of morphine: A prospective survey of common symptoms during repeated dosing for chronic cancer pain
    • Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. American Journal of Hospice and Palliative Care. 2006; 23: 229-35
    • (2006) American Journal of Hospice and Palliative Care , vol.23 , pp. 229-235
    • Glare, P.1    Walsh, D.2    Sheehan, D.3
  • 85
    • 0037758126 scopus 로고    scopus 로고
    • Morphine and alternative opioids in cancer pain: The EAPC recommendations
    • Hanks GW, Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. British Journal of Cancer. 2001; 84: 587-93
    • (2001) British Journal of Cancer , vol.84 , pp. 587-593
    • Hanks, G.W.1    Conno, F.2    Cherny, N.3
  • 86
    • 12344291823 scopus 로고    scopus 로고
    • Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain
    • Hagen NA, Thirlwell M, Eisenhoffer J et al. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. Journal of Pain and Symptom Management. 2005; 29: 80-90
    • (2005) Journal of Pain and Symptom Management , vol.29 , pp. 80-90
    • Hagen, N.A.1    Thirlwell, M.2    Eisenhoffer, J.3
  • 87
    • 0025168461 scopus 로고
    • The effect of prescribed daily dose frequency on patient medication compliance
    • Eisen SA, Miller DK, Woodward RS et al. The effect of prescribed daily dose frequency on patient medication compliance. Archives of Internal Medicine. 1990; 150: 1881-4
    • (1990) Archives of Internal Medicine , vol.150 , pp. 1881-1884
    • Eisen, S.A.1    Miller, D.K.2    Woodward, R.S.3
  • 88
    • 0343580459 scopus 로고    scopus 로고
    • Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain
    • Broomhead A, Kerr R, Tester W et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. Journal of Pain and Symptom Management. 1997; 14: 63-73
    • (1997) Journal of Pain and Symptom Management , vol.14 , pp. 63-73
    • Broomhead, A.1    Kerr, R.2    Tester, W.3
  • 89
    • 84892501827 scopus 로고    scopus 로고
    • Principles of oral analgesic therapy in cancer pain
    • Sykes N, Fallon MT, Patt RB, London: Arnold Publishers
    • Schug SA, Ritchie JE. Principles of oral analgesic therapy in cancer pain. In: Sykes N, Fallon MT, Patt RB (eds). Clinical pain management: cancer pain. London: Arnold Publishers, 2003: 123-41
    • (2003) Clinical Pain Management: Cancer Pain , pp. 123-141
    • Schug, S.A.1    Ritchie, J.E.2
  • 90
    • 28244480795 scopus 로고    scopus 로고
    • Analgesic drugs
    • Rang HP, Dale MM, Ritter JM, Moore PK, 5th edn. New York: Churchill Livingstone
    • Rang HP, Dale MM, Ritter JM, Moore PK. Analgesic drugs. In: Rang HP, Dale MM, Ritter JM, Moore PK (eds). Pharmacology, 5th edn. New York: Churchill Livingstone, 2003: 562-93
    • (2003) Pharmacology , pp. 562-593
    • Rang, H.P.1    Dale, M.M.2    Ritter, J.M.3    Moore, P.K.4
  • 91
    • 0031019623 scopus 로고    scopus 로고
    • Pharmacological characterization of buprenorphine, a mixed agonistantagonist with kappa 3 analgesia
    • Pick CG, Peter Y, Schreiber S, Weizman R. Pharmacological characterization of buprenorphine, a mixed agonistantagonist with kappa 3 analgesia. Brain Research. 1997; 744: 41-6
    • (1997) Brain Research , vol.744 , pp. 41-46
    • Pick, C.G.1    Peter, Y.2    Schreiber, S.3    Weizman, R.4
  • 92
    • 27144543526 scopus 로고    scopus 로고
    • Buprenorphine in cancer pain
    • Davis MP. Buprenorphine in cancer pain. Supportive Care in Cancer. 2005; 13: 878-87
    • (2005) Supportive Care in Cancer , vol.13 , pp. 878-887
    • Davis, M.P.1
  • 94
    • 33745960058 scopus 로고    scopus 로고
    • Long-term management of chronic pain with transdermal buprenorphine: A multicenter, open-label, follow-up study in patients from three short-term clinical trials
    • Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clinical Therapeutics. 2006; 28: 943-52
    • (2006) Clinical Therapeutics , vol.28 , pp. 943-952
    • Likar, R.1    Kayser, H.2    Sittl, R.3
  • 95
    • 33745036516 scopus 로고    scopus 로고
    • Transdermal buprenorphine in cancer pain and palliative care
    • Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliative Medicine. 2006; 20 (Suppl. 1): s25-30
    • (2006) Palliative Medicine , vol.20 , pp. s25-s30
    • Sittl, R.1
  • 96
    • 11144344197 scopus 로고    scopus 로고
    • Pharmacology of high-dose buprenorphin
    • Kintz P, Marquet P, Totowa, NJ: Humana Press
    • Marquet P. Pharmacology of high-dose buprenorphin. In: Kintz P, Marquet P (eds). Buprenorphine therapy of opiate addiction. Totowa, NJ: Humana Press, 2002: 1-11
    • (2002) Buprenorphine Therapy of Opiate Addiction , pp. 1-11
    • Marquet, P.1
  • 97
    • 18944380310 scopus 로고    scopus 로고
    • Transdermal buprenorphine in the treatment of chronic pain
    • Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Review of Neurotherapeutics. 2005; 5: 315-23
    • (2005) Expert Review of Neurotherapeutics , vol.5 , pp. 315-323
    • Sittl, R.1
  • 98
    • 0031018574 scopus 로고    scopus 로고
    • Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control
    • Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997; 53: 109-38
    • (1997) Drugs , vol.53 , pp. 109-138
    • Jeal, W.1    Benfield, P.2
  • 99
    • 33750322229 scopus 로고    scopus 로고
    • A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer
    • Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clinical Journal of Pain. 2006; 22: 805-11
    • (2006) Clinical Journal of Pain , vol.22 , pp. 805-811
    • Portenoy, R.K.1    Taylor, D.2    Messina, J.3    Tremmel, L.4
  • 100
    • 33847154665 scopus 로고    scopus 로고
    • Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate
    • Darwish M, Kirby M, Robertson Jr. P et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. Journal of Clinical Pharmacology. 2007; 47: 343-50
    • (2007) Journal of Clinical Pharmacology , vol.47 , pp. 343-350
    • Darwish, M.1    Kirby, M.2    Robertson, P.3
  • 101
    • 0028905662 scopus 로고
    • Ketobemidone, methadone and pethidine are non-competitive N-methylD-aspartate (NMDA) antagonists in the rat cortex and spinal cord
    • Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methylD-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neuroscience Letters. 1995; 187: 165-8
    • (1995) Neuroscience Letters , vol.187 , pp. 165-168
    • Ebert, B.1    Ersen, S.2    Krogsgaard-Larsen, P.3
  • 102
    • 0036439851 scopus 로고    scopus 로고
    • Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence
    • Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clinical Pharmacokinetics. 2002; 41: 1153-93
    • (2002) Clinical Pharmacokinetics , vol.41 , pp. 1153-1193
    • Eap, C.B.1    Buclin, T.2    Baumann, P.3
  • 103
    • 0030928512 scopus 로고    scopus 로고
    • An update on the clinical use of methadone for cancer pain
    • Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 1997; 70: 109-15
    • (1997) Pain , vol.70 , pp. 109-115
    • Ripamonti, C.1    Zecca, E.2    Bruera, E.3
  • 105
    • 4544275588 scopus 로고    scopus 로고
    • Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study
    • Bruera E, Palmer JL, Bosnjak S et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of Clinical Oncology. 2004; 22: 185-92
    • (2004) Journal of Clinical Oncology , vol.22 , pp. 185-192
    • Bruera, E.1    Palmer, J.L.2    Bosnjak, S.3
  • 106
    • 0035367176 scopus 로고    scopus 로고
    • Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study
    • Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. Journal of Clinical Oncology. 2001; 19: 2898-904
    • (2001) Journal of Clinical Oncology , vol.19 , pp. 2898-2904
    • Mercadante, S.1    Casuccio, A.2    Fulfaro, F.3
  • 107
    • 10044224657 scopus 로고    scopus 로고
    • Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain
    • Benitez-Rosario MA, Feria M, Salinas-Martin A et al. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer. 2004; 101: 2866-73
    • (2004) Cancer , vol.101 , pp. 2866-2873
    • Benitez-Rosario, M.A.1    Feria, M.2    Salinas-Martin, A.3
  • 110
    • 0037468688 scopus 로고    scopus 로고
    • Opioids and chronic neuropathic pain
    • Foley KM. Opioids and chronic neuropathic pain. New England Journal of Medicine. 2003; 348: 1279-81
    • (2003) New England Journal of Medicine , vol.348 , pp. 1279-1281
    • Foley, K.M.1
  • 111
    • 0033508630 scopus 로고    scopus 로고
    • Role of methadone in the management of pain in cancer patients
    • Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. Oncology. 1999; 13: 1275-82
    • (1999) Oncology , vol.13 , pp. 1275-1282
    • Bruera, E.1    Neumann, C.M.2
  • 113
    • 33646151412 scopus 로고    scopus 로고
    • Oxycodone for cancer-related pain: Meta-analysis of randomized controlled trials
    • Reid CM, Martin RM, Sterne JA et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Archives of Internal Medicine. 2006; 166: 837-43
    • (2006) Archives of Internal Medicine , vol.166 , pp. 837-843
    • Reid, C.M.1    Martin, R.M.2    Sterne, J.A.3
  • 114
    • 0030819187 scopus 로고    scopus 로고
    • Controlled-release oxycodone and morphine in cancer related pain
    • Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain. 1997; 73: 37-45
    • (1997) Pain , vol.73 , pp. 37-45
    • Heiskanen, T.1    Kalso, E.2
  • 115
    • 0023795011 scopus 로고
    • Hallucinations during morphine but not during oxycodone treatment
    • Kalso E, Vainio A. Hallucinations during morphine but not during oxycodone treatment. Lancet. 1988; 2: 912
    • (1988) Lancet , vol.2 , pp. 912
    • Kalso, E.1    Vainio, A.2
  • 116
    • 16844373756 scopus 로고    scopus 로고
    • Single-and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets
    • Adams MP, Ahdieh H. Single-and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs in R&D. 2005; 6: 91-9
    • (2005) Drugs in R&D , vol.6 , pp. 91-99
    • Adams, M.P.1    Ahdieh, H.2
  • 118
    • 0017580705 scopus 로고
    • Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer
    • Beaver WT, Wallenstein SL, Houde RW, Rogers A. Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. Journal of Clinical Pharmacology. 1977; 17: 186-98
    • (1977) Journal of Clinical Pharmacology , vol.17 , pp. 186-198
    • Beaver, W.T.1    Wallenstein, S.L.2    Houde, R.W.3    Rogers, A.4
  • 119
    • 13244272132 scopus 로고    scopus 로고
    • Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study
    • Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Supportive Care in Cancer. 2005; 13: 57-65
    • (2005) Supportive Care in Cancer , vol.13 , pp. 57-65
    • Sloan, P.1    Slatkin, N.2    Ahdieh, H.3
  • 122
    • 0034569462 scopus 로고    scopus 로고
    • D-morphine, but not L-morphine, has low micromolar affinity for the noncompetitive N-methyl-D-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain
    • Stringer M, Makin MK, Miles J, Morley JS. D-morphine, but not L-morphine, has low micromolar affinity for the noncompetitive N-methyl-D-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain. Neuroscience Letters. 2000; 295: 21-4
    • (2000) Neuroscience Letters , vol.295 , pp. 21-24
    • Stringer, M.1    Makin, M.K.2    Miles, J.3    Morley, J.S.4
  • 123
    • 0036323891 scopus 로고    scopus 로고
    • Clinical pharmacology of opioids for pain
    • Inturrisi CE. Clinical pharmacology of opioids for pain. Clinical Journal of Pain. 2002; 18: S3-13
    • (2002) Clinical Journal of Pain , vol.18 , pp. S3-S13
    • Inturrisi, C.E.1
  • 124
    • 33847139761 scopus 로고    scopus 로고
    • Levorphanol: The forgotten opioid
    • Prommer E. Levorphanol: the forgotten opioid. Supportive Care in Cancer. 2007; 15: 259-64
    • (2007) Supportive Care in Cancer , vol.15 , pp. 259-264
    • Prommer, E.1
  • 125
    • 37849014818 scopus 로고    scopus 로고
    • Opioid agonists and antagonists
    • Stoelting RK, Hillier SC, 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins
    • Stoelting RK, Hillier SC. Opioid agonists and antagonists. In: Stoelting RK, Hillier SC (eds). Pharmacology and physiology in anesthetic practice, 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2006: 87-126
    • (2006) Pharmacology and Physiology in Anesthetic Practice , pp. 87-126
    • Stoelting, R.K.1    Hillier, S.C.2
  • 126
    • 17844387368 scopus 로고    scopus 로고
    • Plasma concentrations of meperidine and normeperidine following continuous intrathecal meperidine in patients with neuropathic cancer pain
    • Vranken JH, van der Vegt MH, van Kan HJ, Kruis MR. Plasma concentrations of meperidine and normeperidine following continuous intrathecal meperidine in patients with neuropathic cancer pain. Acta Anaesthesiologica Scandinavica. 2005; 49: 665-70
    • (2005) Acta Anaesthesiologica Scandinavica , vol.49 , pp. 665-670
    • Vranken, J.H.1    Van Der Vegt, M.H.2    Van Kan, H.J.3    Kruis, M.R.4
  • 127
  • 128
    • 0026012840 scopus 로고
    • Opioid agonist-antagonist drugs in acute and chronic pain states
    • Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs. 1991; 41: 326-44
    • (1991) Drugs , vol.41 , pp. 326-344
    • Hoskin, P.J.1    Hanks, G.W.2
  • 130
    • 0032076332 scopus 로고    scopus 로고
    • Nalmefene: A long-acting opioid antagonist. Clinical applications in emergency medicine
    • Wang DS, Sternbach G, Varon J. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. Journal of Emergency Medicine. 1998; 16: 471-5
    • (1998) Journal of Emergency Medicine , vol.16 , pp. 471-475
    • Wang, D.S.1    Sternbach, G.2    Varon, J.3
  • 131
    • 2942586206 scopus 로고    scopus 로고
    • Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects
    • discussion 9-22
    • Yuan CS. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects. Journal of Supportive Oncology. 2004; 2: 111-17; discussion 9-22
    • (2004) Journal of Supportive Oncology , vol.2 , pp. 111-117
    • Yuan, C.S.1
  • 132
    • 20144366569 scopus 로고    scopus 로고
    • Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction a 21-day treatment-randomized clinical trial
    • Paulson DM, Kennedy DT, Donovick RA et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction a 21-day treatment-randomized clinical trial. Journal of Pain. 2005; 6: 184-92.
    • (2005) Journal of Pain , vol.6 , pp. 184-192
    • Paulson, D.M.1    Kennedy, D.T.2    Donovick, R.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.